Markets:

Overview

News

Currencies

International

Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

20.81 -2.61 (-11.14%)

Streaming Delayed Price Updated: 11:24 AM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

February 23, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

February 13, 2024

From Legend Biotech Corporation

Via Business Wire

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

Key Takeaways From Legend Biotech Analyst Ratings ↗

December 19, 2023

Via Benzinga

Analyst Ratings for Legend Biotech ↗

October 18, 2023

Via Benzinga

The Latest Analyst Ratings for Legend Biotech ↗

August 16, 2023

Via Benzinga

As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗

January 10, 2024

Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.

Via Benzinga

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

January 03, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Legend Biotech Corporation

Via Business Wire

The Latest Analyst Ratings for Legend Biotech ↗

July 20, 2023

Via Benzinga

The Latest Analyst Ratings for Legend Biotech ↗

June 13, 2023

Via Benzinga

Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast ↗

June 06, 2023

Via Benzinga

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

December 11, 2023

From Legend Biotech Corporation

Via Business Wire

Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say ↗

December 11, 2023

Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or

Via Benzinga

Earnings Scheduled For November 20, 2023 ↗

November 20, 2023

Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.

Via Benzinga

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

November 20, 2023

From Legend Biotech Corporation

Via Business Wire

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On ↗

November 16, 2023

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

Via The Motley Fool

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

November 13, 2023

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

November 07, 2023

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

November 02, 2023

From Legend Biotech Corporation

Via Business Wire

Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug ↗

October 18, 2023

Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,

Via Benzinga

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

August 15, 2023

From Legend Biotech Corporation

Via Business Wire

3 Biotech Stocks That Analysts Are Drooling Over ↗

August 07, 2023

With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.

Via InvestorPlace

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

August 03, 2023

From Legend Biotech Corporation

Via Business Wire

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗

June 20, 2023

A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.

Via Investor's Business Daily

Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗

June 10, 2023

HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...

Via Talk Markets

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

June 06, 2023

From Legend Biotech Corporation

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.